NDA 022044 · Msd Sub Merck
Janumet
Metformin Hydrochloride, Sitagliptin Phosphate · Oral
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Mar 30, 2007
Approved uses
8
Original approval plus efficacy supplements
Registered trials
2,828
753 Phase 3, 150 recruiting
FAERS reports
19,518
13,277 serious, 2,052 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ] . Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast,...
What it is approved for
From the label in effect Aug 11, 2026.
JANUMET ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use JANUMET should not be used in patients with type 1 diabetes mellitus. JANUMET has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET [see Warnings and Precautions (5.2) ]. JANUMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: JANUMET should not be used in patients with type 1 diabetes. ( 1 ) JANUMET has not been studied in patients with a history of pancreatitis. ( 1 , 5.2 )
Mechanism: JANUMET JANUMET combines two antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes mellitus: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin HCl, a member of the biguanide class. Sitagliptin Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by sitagliptin, thereby increasing and prolonging the action of these hormones. Incretin hormones,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 4, 2020 Supplement 48 · Efficacy · priority review LabelLetter
- Aug 12, 2019 Supplement 46 · Efficacy LetterLabel
- Sep 24, 2010 Supplement 14 · Efficacy LabelLetter
- Feb 26, 2010 Supplement 12 · Efficacy LetterLabel
- Feb 26, 2010 Supplement 10 · Efficacy LetterLabel
- Feb 26, 2008 Supplement 4 · Efficacy LabelLetter
- Feb 26, 2008 Supplement 3 · Efficacy LabelLetter
- Mar 30, 2007 Original approval · Type 4 - New Combination Other Important Information from FDALabelReview
2 products under this application
- JANUMET · METFORMIN HYDROCHLORIDE 500MG; SITAGLIPTIN PHOSPHATE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB
- JANUMET · METFORMIN HYDROCHLORIDE 1GM; SITAGLIPTIN PHOSPHATE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Metformin" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- ACTIV-6: COVID-19 Study of Repurposed MedicationsPivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT04885530 · 10,956 participants · Start Jun 8, 2021 · Primary completion Apr 29, 2024
Drug: Ivermectin; Fluvoxamine and 3 more · For: Covid19
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 110 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
Juliana CN ChanAcademic, hospital or other
NCT06693934 · 9,000 participants (planned) · Start Nov 23, 2024 · Primary completion Oct 2027
Drug: Medication · For: Diabetes; Pre Diabetes; Hypertension and 2 more
Sites: Hong Kong, Hong Kong
- Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive SubjectsPivotal-lookingStatus unknown
Ramathibodi HospitalAcademic, hospital or other
NCT01364675 · 8,900 participants (planned) · Start Jan 2012 · Primary completion Jul 2016
Drug: Metformin+Enalapril+Simvastatin; Placebo tablet · For: Pre-diabetes; Pre-hypertension
Sites: Muang District, Thailand
- Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomesPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT02915198 · 7,410 participants (planned) · Start Apr 3, 2023 · Primary completion Sep 28, 2029
Drug: Metformin XR; Placebo · For: Prediabetic State; Atherosclerosis; Metformin
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 40 sites in all
- A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)Pivotal-lookingRecruiting
Kyu Chang WonAcademic, hospital or other
NCT06627322 · 5,950 participants (planned) · Start Nov 21, 2024 · Primary completion Sep 30, 2029
Drug: Dual-combination therapy; Triple-combination therapy · For: Type 2 Diabetes
Sites: Daegu, South Korea; Seoul, South Korea
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01709305 · 5,570 participants · Start Nov 8, 2012 · Primary completion Apr 17, 2015
Drug: Metformin; Sitagliptin and 4 more · For: Type 2 Diabetes Mellitus
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased1,318
- diarrhoea1,214
- nausea1,004
- drug ineffective886
- acute kidney injury823
- fatigue821
- vomiting706
- weight decreased671
- dyspnoea581
- pancreatic carcinoma575
- pancreatitis575
- dizziness573
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 39 |
| 2008 | 131 |
| 2009 | 254 |
| 2010 | 384 |
| 2011 | 537 |
| 2012 | 839 |
| 2013 | 1,225 |
| 2014 | 1,686 |
| 2015 | 2,188 |
| 2016 | 1,897 |
| 2017 | 1,497 |
| 2018 | 1,634 |
| 2019 | 1,481 |
| 2020 | 1,378 |
| 2021 | 1,149 |
| 2022 | 909 |
| 2023 | 801 |
| 2024 | 664 |
| 2025 | 505 |
| 2026 | 320 |
Recalls
1 FDA enforcement reports for this application.
Mar 31, 2022 · Class II · Terminated
Presence of foreign substance: Presence of stainless steel particulates in tablets.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Janumet (Sitagliptin Phos/Metformin HCl)
2024 spending
$709M
Beneficiaries
159,321
743,903 claims
Per beneficiary
$4,451
$8.97 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $791,886,114 |
| 2021 | $814,640,687 |
| 2022 | $815,605,370 |
| 2023 | $798,865,849 |
| 2024 | $709,178,278 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Greff D, Juhász AE, Váncsa S, et al. · Reprod Biol Endocrinol 2023 · Meta-Analysis, Systematic Review
- Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M, Coppola A, Sesa V, et al. · World J Gastroenterol 2024 · Meta-Analysis, Systematic Review
- Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.
Melin J, Forslund M, Alesi S, et al. · J Clin Endocrinol Metab 2024 · Meta-Analysis, Systematic Review
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Tsapas A, Avgerinos I, Karagiannis T, et al. · Ann Intern Med 2020 · Comparative Study, Research Support, Non-U.S. Gov't
- The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Melin J, Forslund M, Alesi S, et al. · Eur J Endocrinol 2023 · Meta-Analysis, Systematic Review
- Metformin improves survival in patients with concurrent diabetes and small cell lung cancer: a meta-analysis.
Fan H, Bai S, Guan X, et al. · Minerva Endocrinol (Torino) 2023 · Meta-Analysis, Systematic Review
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.